Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher's proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to the closing price of QIAGEN's common stock on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the transaction. Thermo Fisher will commence a tender offer to acquire all of the ordinary shares of QIAGEN.
The NCI awarded a 5-year, $8.3 million research grant to Weill Cornell Medicine, Moffitt Cancer Center and Universidade de Sao Paulo in Brazil to investigate strategies to prevent HPV-related cancers among individuals with HIV.
BioNTech (Nasdaq: BNTX, “BioNTech”) and Neon Therapeutics, Inc. (Nasdaq: NTGN, “Neon”) today announced that they have entered into a definitive merger agreement under which BioNTech will acquire Neon in an all-stock transaction valued at approximately $67.0 million.
Fujifilm Holdings Corp (4901.T) said on Tuesday it is considering buying Hitachi Ltd’s (6501.T) diagnostic imaging business, as the Japanese photocopier and camera manufacturer aims to build up its medical business.
The STADA Group, a global manufacturer of high-quality generic drugs and consumer healthcare products, continues its growth trajectory in Europe. The company, headquartered in Germany, announced today that it is acquiring the pharmaceutical business of Biopharma, one of the key pharmaceutical producers in Ukraine.
Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death